US Stock MarketDetailed Quotes
NKGN NKGEN BIOTECH
- 0.401
- +0.006+1.54%
Close Sep 27 16:00 ET
- 0.390
- -0.011-2.84%
Post 17:54 ET
14.26MMarket Cap-105P/E (TTM)
0.403High0.380Low116.64KVolume0.395Open0.395Pre Close45.88KTurnover0.72%Turnover RatioLossP/E (Static)35.52MShares6.70052wk High-0.20P/B6.47MFloat Cap0.37152wk Low--Dividend TTM16.11MShs Float12.880Historical High--Div YieldTTM5.76%Amplitude0.371Historical Low0.393Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
NKGEN BIOTECH Stock Forum
NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
Two of the first three patients in the Phase 1 cohort of the Phase 1/2a clinical trial, treated at the highest dose of 6 billion cells per treatment, were found to have improved CDR-SB cognitive scores, resulting in a clinical upgrade from moderate AD to mild AD after only three months on therapy.
First patient...
A 90% improved cognitive function for Alzheimer’s disease is a very impressive outcome for this trial.
NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
NKGen Biotech presented new positive data on its SNK01 therapy for Alzheimer's disease at the 2024 AAIC.
The study showed that SNK01, a cryopreserved autologous non-genetically modified NK cell product, can effectively reduce α-synuclein (α-syn) protein levels in the cerebrospinal fluid of Alzheimer's patients. This is significant as increased α-syn ...
No comment yet